The facility, located in Dessau, Germany, will go back to producing Takeda’s dengue vaccine candidate after a three-month period.
Takeda has agreed to help manufacture three different COVID-19 vaccines. The drugmaker has already begun manufacturing Moderna and Novavax vaccines to provide rapid and sustained COVID-19 vaccine access in Japan.
More articles on pharmacy:
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Gilead, Merck co-developing long-acting HIV treatment
